Press Room

Press Release / Oct 12, 2015

Hovione Appoints Kristine Senft Vice President, Sales and Marketing

Ms. Senft joined Hovione on the 1st October and will succeed Mr. Dave Hoffman Vice President Sales and Business Development when he retires in April 2016.

Loures, Portugal, October 12, 2015 – Hovione announced today the appointment of Ms. Kristine Senft as Vice President Sales and Marketing. Ms. Senft joined Hovione on the 1st October and will succeed Mr. Dave Hoffman Vice President Sales and Business Development when he retires in April 2016. Ms. Senft was most recently with DSM and brings a vast experience in Sales and Marketing. Based in East Windsor, New Jersey, Ms. Senft will report to Guy Villax, Hovione’s Chief Executive Officer.

“Hovione is delighted to welcome Ms. Senft to our management team. I very much look forward to working with Kristine.  Kristine brings to Hovione exactly what we need as we enter this next phase of growth”, said Guy Villax.

“I am delighted to join Hovione, a company with a dynamic team and a strong history that understands the nature of leading through innovation. I look forward to building on what has been achieved by Hovione to date in its creation of solutions for customers”, said Ms. Senft.

Before joining Hovione, Ms. Senft previously served various roles as a Business Unit Director, DSM Biomedical and before that as SVP, Marketing and Sales, DSM Pharmaceutical Chemicals where she led both regional and global marketing and sales organizations while experiencing expatriate life in Vienna, Austria, working with many of the top global pharma and biopharma companies. She also worked for Albemarle Corporation for many years in mainly Sales and Business Management roles in their Fine Chemicals and Pharmaceutical API businesses.

Ms. Senft was also Co-Chair of the Women’s Initiative Network at Albemarle and was an executive member of the DSM Diversity Council. During her career she served on the Society of Chemical Manufacturers Association (SOCMA) Communications Committee and Membership Committee for several years. She is an active supporter of the Drug, Chemical and Associated Technologies Association (DCAT), DCAT Week and has recently served on the DCAT Board of Directors. While residing in Europe she was also associated with the European Fine Chemicals Group (EFCG).

Ms. Senft graduated from Eastern Illinois University with a BSc in Chemistry. She recently (2014) completed the Executive Leadership Program with DSM / Wharton, University of Pennsylvania.

About Hovione
Hovione is an international company with over 50 years’ experience in the development and compliant manufacture of Active Pharmaceutical Ingredients and Drug Product Intermediates. With four FDA inspected sites in the U.S., China, Ireland, and Portugal, the company focuses on the most demanding customers, in the most regulated markets. The company also offers branded pharmaceutical customers services for the development and compliant manufacture of innovative new drugs, is able to support highly potent compounds and offers proprietary product development and licensing opportunities for drug products. In the inhalation area, Hovione is the only independent company offering such a broad range of services. Hovione is a member of Rx-360, EFCG and APIC and is active in the standard setting process of our industry, this reflects its commitment to higher global industry standards. 

 

Also in the Press Room

See All

Hovione’s Eunice Costa Shares Insights on Inhaled Medicine Formulation in Pharmaceutical Technology eBook The demand for efficient inhalation therapies is higher than ever. At Hovione we are focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes.  To learn more about or work, do not miss the contribution of Eunice Costa, our R&D Director for Inhalation & Advanced Drug Delivery, in the latest Pharmaceutical Technology eBook – “Trends in Formulation”.  In her interview, Eunice discusses key challenges and considerations in formulating inhaled medicines, emphasizing the importance of excipient selection, device compatibility, and patient-centric design for successful drug delivery to the lungs. With respiratory diseases at the forefront, especially following the COVID-19 pandemic, the demand for efficient inhalation therapies is higher than ever. Eunice sheds light on how Hovione is tackling these demands by focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes. Explore Eunice Costa’s full insights on this crucial area of drug development in Pharmaceutical Technology's September 2024 eBook. This resource provides an in-depth look into the complexities of inhaled drug formulations and the exciting innovations shaping the future of respiratory treatments.   Read the full article at Pharmaceutical Technology eBook Read the Trends in Formulation eBook at PharmTech  

Article

Formulating Inhaled Medicines

Sep 24, 2024

Lisbon, Portugal – Hovione, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, Hovione joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At Hovione, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of Hovione. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” Hovione will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with Hovione’s sustainability ambitions.  Hovione remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

Hovione Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024